Elevated levels of eukaryotic initiation factor 4E (eIF4E) are implicated in neoplasia, with cumulative evidence pointing to its role in the etiopathogenesis of hematological diseases. As a node of convergence for several oncogenic signaling pathways, eIF4E has attracted a great deal of interest from biologists and clinicians whose efforts have been targeting this translation factor and its biological circuits in the battle against leukemia. The role of eIF4E in myeloid leukemia has been ascertained and drugs targeting its functions have found their place in clinical trials. Little is known, however, about the pertinence of eIF4E to the biology of lymphocytic leukemia and a paucity of literature is available in this regard that prospectively evaluates the topic to guide practice in hematological cancer. A comprehensive analysis on the significance of eIF4E translation factor in the clinical picture of leukemia arises, therefore, as a compelling need.
Introduction
Leukemic transformation is a convoluted biological process embracing changes in a gene cascade, which ultimately conduces to the clonal expansion of defective stem cells. Cellular growth and differentiation within the hematopoietic lineage are compromised by the build-up of genetic lesions, frequently resulting in altered tumour suppressive activities. These genetic events-along with epigenetic occurrences-induce leukemogenesis, the course of which has been correlated with deregulated levels of specific proteins. A convincing body of evidence points at aberrant control of protein synthesis as a condition favourable to malignant transformation, ultimately contributing to lymphoid neoplasmas (Ruggero et al. 2004) . Emerging models reference the eukaryotic translation initiation factor 4E (eIF4E) as a key player in leukemic transformation: eIF4E mRNA and protein expression levels have been observed up-regulated in human malignancies as non-Hodgkin lymphoma (NHL) (Wang et al. 1999) , acute (AML) and chronic myelogenous leukemia (CML) (Topisirovic et al. 2003) , and acute lymphoblastic leukemia (ALL) (Zhu et al. 2013) . Promises exist for novel drug design where the translational apparatus represents a primary therapeutic target. This review explores the significance of eIF4E in the context of lymphoblastic leukemias, delving into eIF4E factor regulation and clinical implications in the light of its long-established role in translation and a newly emerging one in leukemogenesis. Emphasis is on pathways that undergo dysregulation in the leukemic status while upholding a neoplastic phenotype through protein synthesis deregulation. The topic of myeloid leukemia has been dealt with by numerous authors; therefore, it will not be outlined hereinafter. Excellent reviews on the subject are available to interested readers with regard to the biology of myeloid leukemia (Shivarov and Bullinger 2014) , its epigenetic landscape (Paluch et al. 2016) , and current drug therapy (Jabbour 2016 , Kadia et al. 2016 .
The Lymphoblastic Leukemic State
Acute lymphoblastic leukemia (ALL) is a clonal malignancy that encompasses a group of precursor stage B/T lymphoid cells during the earliest stages of their development, therefore impeding differentiation and maneuvering aberrant cell proliferation. The clinical heterogeneity of the disease progression and outcome, when comparing the pediatric population to adults, portrays quite distinctive biological subtypes. ALL is the most ordinary malignancy diagnosed in children (reviewed in Bhojwani 2015), accounting for over a quarter of all childhood cancers.
Subtypes of ALL include both precursor B and T acute lymphoblastic leukemia, Burkitt's leukemia, and acute biphenotypic leukemia, yet this review will focus on B and T lymphoblastic leukemias exclusively. The preponderance of cases are of B-cell origin; however, ALL can besides arise from lymphoblasts committed to the T-cell lineage, a form of leukemia in which the malignant cells express immature Tcell immunophenotypes. Typified by small to medium-sized blast cells with inadequate cytoplasm, T-ALL portends an unfavourable prognostic outlook than B-precursor ALL in that it is characterized by chemotherapy resistance and frequent relapse (Tariq et al. 2009 ). Current treatment regimens encompass risk-adapted chemotherapy, hematopoietic stem-cell transplantation, and comfort care; improved therapy strategies for T-ALL with reduced long-term toxicities remain nevertheless a compelling need.
Chronic lymphocytic leukemia (CLL) is a condition characterized by a progressive accumulation of monoclonal B lymphocytes that preferentially affects adults over the age of 55, a disproportionate number of whom are males; while it occasionally occurs in younger adults, it appears to leave children mostly unaffected. As a low-grade lymphoproliferative disorder, CLL follows an indolent clinical course and, owing to its relatively longer survival rate, is the most common leukemia within the Western world's adult population (Redaelli et al. 2004 ). B-cell chronic lymphocytic leukemia (B-CLL) has the highest diagnostic recurrence among clinical entities of leukemic nature and is characterized by the progressive accumulation of immunologically competent, phenotypically mature B lymphocytes. T-and B-cells are usually associated with specific CD markers (Montillo et al. 2005 , Niu et al. 2013 ) that discriminate on cell type (T-from -B) and diverse maturation stages; however, reports exist for cases of B-CLL that aberrantly co-express two T-cell-associated antigens (Espinosa et al. 2003 , Jani et al. 2007 . One of the most aggressive CLL subtypes is B-cell prolymphocytic leukemia (PLL), an extremely rare disease comprising less than 1% of B cell leukemias. This kind of leukemia may occur by itself, concurrently with CLL or, in due course, CLL may turn into PLL which progressively tends to worsen more quickly (Yamamoto and Goodman 2008) . CLL differs from other leukemic diseases staging since most patients are asymptomatic or only mildly symptomatic at the time of diagnosis and do not require immediate treatment. Once a so-called "incurable" disease in the elderly, CLL can nowadays be fairly effectively alleviated with current standard treatments.
Protracted remissions and enhancements in survival rates are improving, albeit a complete remission stage is unlikely to be attained with the current state of medical intervention and novel therapeutic strategies and drug candidates are utterly awaited.
The Eukaryotic Initiation Factor 4E
In eukaryotes, a majority of cellular mRNAs is translated via cap-dependent translation (reviewed in Merrick et al. 2004, Sonenberg and Hinnebusch 2009) . The m7GpppN cap structure present at the 5'-end of messenger ribonucleic acids is bound by eIF4E as a part of the eIF4F complex (Grifo et al. 1983 , Sonenberg et al. 1978 . A multisubunit structural entity, eIF4F consists of the rate limiting factor eIF4E and its interaction partners, the scaffolding protein eIF4G and the DEAD-box helicase eIF4A. eIF4E role is, however, not constrained to the pre-initiation complex: this key translation factor also functions in mRNA-related events as nucleocytoplasmic transport of mRNA, its sequestration and protection against exonuclease decay. Critical to gene expression, the step of translation initiation presides over the making of individual protein components by restraining the levels of cap-binding complex elements and mRNAs. Perturbations over translation control have dramatic biological effects and are a primary occurrence in malignancies (Ruggero et al. 2004) . The least abundant of the initiation factors, eIF4E is overexpressed in many cancers and plays pivot roles in the development and progression of hematological malignancies in animal models and humans (Wang et al. 1999) , rendering it an alluring target for the treatment of leukemias. The transformation activity of eIF4E is, however, not limited to its role in translation: close ties exist between eIF4E-dependent mRNA export and oncogenic transformation (Culjkovic-Kraljacic et al. 2012) . The stability of eIF4E mRNA (Topisirovic et al. 2009 ) and dysregulation of related cellular processes as P-bodies and stress granules formation (Andrei et al. 2005 , Kedersha et al. 2005 , Frydryskova et al. 2016 could also contribute to eIF4E transformative capacity and deserve further investigation. Translational control of eIF4E activity is multi-level regulated by diverse cellular processes (Fig. 1) . Among the better understood are the phosphorylation event which allows eIF4E to bind the 5' cap structure, the regulation of eIF4E expression level, and its interaction with translational repressor 4E-BPs. Translational control of eIF4E expression is implicated in many cancers; concordantly, eIF4E transforming properties have been linked to its ability to promote translation of genes involved in proliferation and survival. Based upon this evidence eIF4E has been acknowledged as an oncoprotein (Mamane et al. 2007) . eIF4E overexpression leads to increased expression of a subset of mRNAs, many of which encoding mediators of the mitogenic response. Among them are the proto-oncogene c-Myc, the core component of the cell cycle machinery cyclin D1, B-cell lymphoma 2 (Bcl-2) protein, cyclin-dependent kinase 2 (CDK-2), the apoptosis inhibitor survivin, and the ornithine decarboxylase enzyme , De Benedetti et al. 1994 , Rosenwald et al. 1995 . At the nuclear level, eIF4E regulates the export-and subsequent expression-of many messenger RNAs implicated in cell cycle progression via the existence of a nucleotide structural element in the 3' UTR of the given transcripts . Deregulation of eIF4E-mediated mRNA export has been shown to play a significant role in lymphomagenesis (Culjkovic-Kraljacic et al. 2016) . In AML cells, most of the eIF4E is found in the nucleus, highlighting the importance to target nuclear mRNA export in addition to effects on translation. Importantly, the movement of eIF4E to the cytoplasmic compartment correlated with remissions (Assouline et al. 2015) . Although prominently relevant, not all dysregulated translation in cancer is driven by eIF4E. Other translation factors play a role in neoplastic transformation via a capdependent mechanism: for instance, overexpression of a number of eIF3 subunit proteins has been proposed to contribute to malignant phenotypes (Zhang et al. 2007) .
Translational control of immunological function via eIF4E
As a site of control over the immune system's activity, eIF4E has attracted the attention of cancer immunologists. Translational control of immunological function via the eIF4E node endures modulation by mammalian target of rapamycin complex 1 (mTORC1)-dependent inactivation of 4E-BPs and direct phosphorylation by the Mnk1/2 kinases (Beretta et al. 1996 , Ueda et al. 2004 ).
Besides, increases in eIF4E activity can be achieved by affecting its mRNA stability (Topisirovic et al. 2009 ) and/or stimulating its expression at the transcriptional level (e.g., via the transcription factor c-Myc). Given that the majority of eIF4E-sensitive 5'capped transcripts encode proliferation and antiapoptotic polypeptides, it is not surprising that leukemia research efforts have been directed towards modulating eIF4E expression, functions, and inter-related routes. So far, the most satisfactory results have been achieved in the treatment of AML however, a number of exciting research efforts are raising the prospect of significant headways in the cure of lymphocytic leukemias.
Among its reported activities, eIF4E acts as a downstream effector of the serine/threonine kinase mTOR complex 1 (mTORC1) the elevated activity of which is a prominent feature of cancer cells, including hematological malignancies . As anticipated in the text, eIF4E binds the 5' cap structure present on cellular mRNAs and initiates protein synthesis in virtue of its ability to associate with eukaryotic initiation factor 4G (eIF4G) and helicase eIF4A. Binding of eIF4E to scaffold protein eIF4G is restrained in a competitive manner by translational inhibitors, 4E-binding proteins (4E-BPs); upon mTOR-mediated phosphorylation, 4E-BP1 decreases its affinity for eIF4E and, by freeing the binding site, facilitates the joining of eIF4G thereby enhancing cap-dependent translation. Conversely, induction or activation of the tumour suppressor protein p53 rapidly lead to 4E-BP1 dephosphorylation (Constantinou et al. 2008) , resulting in sequestration of eIF4E, decreased formation of the eIF4F complex and consequent inhibition of protein synthesis. The mTORC1-4E-BPeIF4E pathway is regarded as an important axis that affects the translation of several proteins with central roles in immunology, e.g., the interferon regulatory factor IRF7, trans-acting T-cell-specific transcription factor GATA-3, and the cytokine interleukin 4 (IL-4) (Colina et al. 2008 , Cook and Miller 2010 , Gigoux et al. 2014 .
 eIF4E levels and T cells activation
Signals generated from the T-cell receptor (TCR) can trigger the activation of T cells from their naï ve or quiescent state with a subsequent increase in processes as transcription, synthesis of DNA, and protein synthesis (Cooper 1969, Crabtree and Clipstone 1994) . Polysome profiling analysis shows that activated T cells undergo a rapid increase of their protein synthesis levels, along with an augmented ratio of translation/ribosome (Cooper and Braverman 1977) . An investigation over translation rates looking at eIF4E phosphorylation and effects of TCR stimulation conducted on thymocytes demonstrated a severe change in eIF4E activity following activation of these hematopoietic progenitor cells (Beretta et al. 1998) . Furthermore, activation of human peripheral blood T cells by cross-linking of TCR-CD3 results in a strong increase in translation rates and expression of initiation factors (Mao et al. 1992) . T cell development and activation are usually accompanied by assembly of proteins that require active translation, an early happening in activated T cells; eIF4E protein level increases during the first 24 hours (Boal et al. 1993) and later even double in T cell activation (Nikolcheva et al. 2002) . This event occurs before or concurrently with the cellular appearance of RFLAT-1, a transcription factor of late-activated T lymphocytes-1, and hints to a role for eIF4E in the induction of RFLAT-1 protein expression. Overexpression of eIF4E increases RFLAT-1 protein level, whereas inhibition of Mnk1 -a kinase which phosphorylates eIF4E increasing its affinity for the mRNA cap-diminishes RFLAT-1 production rate (Nikolcheva et al. 2002) . Echoing the notion that RFLAT-1 expression endures a cap-dependent regulation mechanism, involving eIF4E and Mnk1, are data evidencing that Mnk1 and Mnk2 kinases are required for T cell development and activation (Gorentla et al. 2013) . In consideration of these findings, the prospect that eIF4E and its physiological Mnk1/2 kinases might be selectively required for efficient translation of specific protein subsets affecting T cell responses cannot be dismissed.
 eIF4E and memory T lymphocytes generation
The vast majority of lymphocytes is represented by CD4+ T and CD8+ T cells, the immunological memory of which is an essential component of protective immunity. In CLL patients, these cells are functionally impaired and exhibit features of T cells exhaustion (Riches et al. 2013) . Therefore, kinase 1 (S6K1), eIF4E, and the immunophilin FKBP12) in antigen specific CD8 T lymphocyte cells.
Retroviruses marked by GFP and expressing RNAi for a given gene or a control retrovirus were used to infect lymphocytic choriomeningitis virus (LCMV) specific transgenic CD8 T cells and these transduced cells were then transferred into naïve mice, followed by LCMV infection. Pursing more insight into mTOR-regulated cell memory formation, the authors examined the role of S6K1 and eIF4E: knockdown of such mTORC1 downstream effectors significantly enhanced memory CD8 T cell differentiation, thereby suggesting that mTOR exerts its effect through these downstream proteins (Araki et al. 2009 ).
 The mTORC1-4E-BP-eIF4E signaling pathway and cell cycle in lymphocytes Cellular protein synthesis plays an explicit role in cell cycle progression. Appropriate cell size and geometry are prerequisites to enter and successfully complete the cell division process. Altogether, a growing body of literature indicates eIF4E as a mediator of mTOR-dependent cell cycle control.
Fingar and colleagues (2004) identified the 4E-BP-eIF4E pathway as one of the major mTORdependent downstream signaling routes in mediating G1 phase progression. The expression level of eIF4E is the determining factor in whether eIF4E triggers a negative feedback loop to constrain deviant cell cycle progression and proliferation. Interestingly, cells overexpressing eIF4E displayed: a) a minor, however significant, acceleration of S phase entry when rapamycin-treated; b) an increase rate of G1 phase progression from quiescence to S phase in a rapamycin-free environment.
Simultaneous downregulation of both S6K1 and 4E-BP-eIF4E pathways impedes G1 phase progression to a degree comparable to that elicited by mTOR inhibitor rapamycin (Fingar et al. 2004 ).
The transitional repressors 4E-BPs are key mTOR effectors controlling growth and proliferation in activated B and T cells. Making use of an inducible in vivo system So et al. (2016) showed that inhibiting eIF4E was sufficient to impede lymphocytes growth and proliferation. Accordingly, deletion of 4E-BPs partially rescued B cells from the effects of mTOR inhibition. In lymphocytes, rapamycin disrupted eIF4E function due to an abundance of 4E-BP2 over 4E-BP1 in these specific cells and their greater sensitivity to this drug. It was concluded that 4E-BP1/eIF4E route is rapamycin sensitive in lymphocytic cells only where it affects clonal expansion by coordinating both growth and proliferation (So et al. 2016) .
 eIF4E and Mnk1/2-direct phosphorylation events consequently, it competes for eIF4E:RNA association, changes the eIF4E subcellular localization and disrupts eIF4E-mediated nuclear-cytoplasmic mRNA export , Kentsis et al. 2004 . A ribavirin-induced switch from nuclear to cytoplasmic eIF4E localization has also been observed in blast cells during clinical studies (Assouline et al. 2009 , Assouline et al. 2015 . Ribavirin was proposed to act as a physical mimic of the m7G moiety thereby blocking eIF4E activity (Kentsis et al. 2004) ; controversially, two independent groups reported on its incapability to function as an mRNA cap analog (Westman et al. 2005 , Yan et al. 2005 . Incongruences between the original findings and Westman and reduced growth and foci formation in mouse NIH 3T3 fibroblasts and human U2OS osteosarcoma cell line. Interestingly, the same group observed lower expression of eIF4E3 mRNA in primary human blood specimens from M4/M5 AML patients relative to healthy volunteers . In diffuse large B-cell lymphoma, enhanced eIF4E3 expression partly suppresses eIF4E-driven translation while exhibiting a unique translatome (Landon et al. 2014) . Recent work on two major variants of the human eIF4E3 isoform, has unveiled that eIF4E3_A but not eIF4E3_B
associates with the translation initiation complex (Frydryskova et al. 2016) . At the same time, inability of eIF4E3_A to bind 4E-BPs (Joshi et al. 2004 ) might spare it from the canonical translation control. This raises speculations on whether eIF4E3_A carries out basal translation initiation when eIF4E is repressed. This hypothesis is supported by relocalization of eIF4E3_A to stress granules but not to P-bodies upon a stress insult, whereas canonical eIF4E localizes to both these RNA granules in stress conditions (Frydryskova et al. 2016) . It is tempting to hypothesize that eIF4E3_A might secure translation of specific subset of mRNAs which do not respond to changes directed by cellular pathways controlling eIF4E function in translation initiation.
Final remarks
A thorough understanding of protein synthesis control has a far-reaching potential to shed light on the complex pathogenesis of leukemia, address its clinical management, and develop innovative therapies. We are witnessing an appreciation for targeting factors functioning within the framework of translation initiation as a new opportunity for therapeutic intervention in the realm of the leukemic state. Challenging questions remain yet unanswered concerning leukemic lesions that directly impinge on dysregulated activities of the translational machinery. To identify messenger RNAs pertinent to leukemic transformation, along with components of the translational apparatus that hold leukemogenic potential, would add a crucial piece to the puzzle. Elucidating the clinical significance of eIF4E expression in both ALL and CLL would represent a predictor of clinical outcome and meet a burning medical need for novel targeted therapies and synergistic interventions.
Undoubtedly, it would ease the development of drug combinations and contribute to a refinement in clinical management with the prospect of chemo-free strategies as concrete therapeutic alternatives in patients affected by lymphoblastic leukemias. 
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